ProCE Banner Activity

Beyond Glycemic Control and Weight Reduction: Benefits of Dual Agonists for GIP and GLP-1

Clinical Thought

Here’s my take on the inclusion of a dual GIP/GLP-1 receptor agonist in the therapy selection decision-making process for patients with T2D, considering both their comorbidities and their priorities.

Released: October 05, 2022

Expiration: December 31, 2023

No longer available for credit.

Share

Faculty

Carol Hatch Wysham

Carol Hatch Wysham, MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from

Lilly

Partners

ADCES

ProCE Banner

Faculty Disclosure

Primary Author

Carol Hatch Wysham, MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Carol Hatch Wysham, MD: researcher: Abbott, Corcept, Lilly, Novo Nordisk, Regeneron, Vanda.